Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objective This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents. RESEARCH DESIGN AND METHODS: The primary end point was HbA 1c change from baseline after 26 weeks' treatment. After an 8-week run-in to optimize basal insulin, subjects were randomized (1:1) to mealtime faster aspart ( n = 345) or IAsp ( n = 344), titrated using a simple daily patient-driven algorithm, plus insulin glargine U100 and metformin. Results HbA 1c change was -1.38% (faster aspart) and -1.36% (IAsp); mean HbA 1c was 6.6% for both groups. Faster aspart demonstrated noninferiority versus IAsp in reducing HbA 1c (estimated treatment difference [ETD] [95% CI] -0.02% [-0.15; 0.10]). Both treatments improved postprandial plasma glucose (PPG) control; the PPG increment (liquid meal test) was statistically significant in favor of faster aspart after 1 h (ETD [95% CI] -0.59 mmol/L [-1.09; -0.09]; -10.63 mg/dL [-19.56; -1.69]; P = 0.0198), but not after 2-4 h. Change from baseline in fasting plasma glucose, body weight, and overall severe/blood glucose-confirmed hypoglycemia rates (rate ratio [RR] [95% CI] 1.09 [0.88; 1.36]) were similar between treatments. Postmeal hypoglycemia (0-2 h) rates were 2.27 (faster aspart) and 1.49 (IAsp) per patient-year of exposure (RR [95% CI] 1.60 [1.13; 2.27]). Conclusions Faster…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhaled insulin with a faster peak of action and shorter duration is also available as prandial insulin, with the requirement of using repeated inhaled correctional insulin doses after 1 to 2 hours postmeal.1158,1159”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1159]
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Andrea, D., Kakuk, P., & Judit, S. (2014) · University of Debrecen Electronic Archive (University of Debrecen) · Cited by 1,954
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia was defined according to the ADA classification (17).”
BackgroundMethod
Research works printed but not linked: 1
- Buckley, 2016, Mechanistic analysis into the mode of action of niacinamide in faster-acting insulin aspart, Diabetes Technol Ther, 18, A291
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Self-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., Fernández Landó, L., & Patel, H. (2023) · JAMA · doi:10.1001/jama.2023.20294 · Cited by 156
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lipscombe, L., Butalia, S., Dasgupta, K., Eurich, D. T., MacCallum, L., Shah, B. R., Simpson, S., & Senior, P. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.001 · Cited by 153
Klonoff, D. C., Evans, M. L., Lane, W. S., Kempe, H., Renard, É., DeVries, J. H., Graungaard, T., Hyseni, A., Gondolf, T., & Battelino, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13610 · Cited by 85
Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
Kildegaard, J., Buckley, S. T., Nielsen, R. H., Povlsen, G. K., Seested, T., Ribel, U., Olsen, H. B., Ludvigsen, S., Jeppesen, C. B., Refsgaard, H. H. F., et al. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2578-7 · Cited by 89
Blevins, T., Zhang, Q., Frias, J. P., Jinnouchi, H., & Chang, A. M. (2020) · Diabetes Care · doi:10.2337/dc19-2550 · Cited by 69
“Studies of fastacting insulin aspart in basal-bolus regimens with either insulin glargine or degludec in patients with type 2 diabetes have also demonstrated noninferiority of HbA1c (15,21).”
BackgroundInfluentialHaahr, H., & Heise, T. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00834-5 · Cited by 63
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Recent Advances in Insulin Therapy
Wilson, L. M., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0065 · Cited by 64
“In a phase 3 study of people with T2D only on basal insulin at baseline, the addition of Fiasp was noninferior with regard to change A1c compared with aspart.(31) In addition, this study showed improved 1 h postprandial glucose control with similar hypoglycemia rates.”
Lee, S., & Yoon, K. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0163 · Cited by 68
“In both T1DM and type 2 diabetes mellitus (T2DM) patients, postprandial glucose control was superior with comparable hypoglycemia and tolerability compared with insulin aspart [54,55].”
BackgroundOwens, D. R., & Bolli, G. B. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13963 · Cited by 58
“59 mmol/L) compared with aspart.(66,70) Despite reducing PPG levels in the trials reported, the overall glucose-lowering ability of faster aspart compared with aspart (based on HbA1c levels) was comparable in T2DM(66,70) or slightly better in T1DM.”
ResultBuse, J. B., Carlson, A. L., Komatsu, M., Mosenzon, O., Rose, L., Liang, B., Buchholtz, K., Horio, H., & Kadowaki, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13545 · Cited by 56
“The improved PPG findings reported in the present study, from both meal test and SMBG, are consistent with general findings across the faster aspart clinical trial programme.(14,15,17,18) Furthermore, the results here specifically support the results of the onset 1 study, in which once- or twice-daily detemir in conju…”
ResultUltra-Rapid-Acting Insulins: How Fast Is Really Needed?
Wong, E., & Kroon, L. A. (2021) · Clinical Diabetes · doi:10.2337/cd20-0119 · Cited by 58
Emerging Technologies for Diabetes Care
Bailey, T. S., Walsh, J., & Stone, J. Y. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0115 · Cited by 47
“15,16 The improved effect of Fiasp is also attributed to an earlier suppression of endogenous glucose.”
Senior, P. A., & HRAMIAK, I. M. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.01.004 · Cited by 46
Heise, T., Meiffren, G., Alluis, B., Seroussi, C., Ranson, A., Arrubla, J., Correia, J., Gaudier, M., Soula, O., Soula, R., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13621 · Cited by 40
“Whether the possibly faster offset of action observed with BCLIS prevents the increase in post-meal hypoglycaemia seen with FIA in some of these trials needs to be investigated in appropriately designed head-to-head comparative studies.(11,12) The faster offset of action could be a particular advantage in the setting…”
BackgroundSelf-citationBiosynthetic Human Insulin and Insulin Analogs
Rodbard, H. W., & Rodbard, D. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001089 · Cited by 46
Basu, A., Pieber, T. R., Hansen, A. K., Sach‐Friedl, S., Erichsen, L., Basu, R., & Haahr, H. L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13270 · Cited by 38
“Thus, the present trial provides the mechanism(s), regarding glucose fluxes, behind the reduction in PPG increment with faster aspart compared with IAsp shown in recent clinical trials in individuals with T1D and T2D.8,9 The relative contributions from treatment differences in postprandial glucose Rd and EGP suppressi…”
ResultWhat is the value of faster acting prandial insulin? Focus on ultra rapid lispro
Heise, T., de Oliveira, C. P., Juneja, R., Ribeiro, A., Chigutsa, F. B., & Blevins, T. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14773 · Cited by 38
“This was similar to trends observed with Faster aspart.(45,46)”
ResultDanne, T., Schweitzer, M. A., Keuthage, W., Kipper, S., Kretzschmar, Y., Simon, J., Wiedenmann, T., & Ziegler, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0360 · Cited by 33
“Type 1 diabetes (T1D) is a chronic disease, characterizedby absent or near absent beta-cell function, that requires insulin therapy.1 Patients with T1D are often treated with a regimen of multiple daily injections (MDI), comprising a long-acting basal component and a mealtime bolus component of short-acting insulin.1…”
ResultPossible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes
Aktürk, H. K., Rewers, A. H., Joseph, H., Schneider, N., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0114 · Cited by 38
Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus
Davis, A., Kuriakose, J., & Clements, J. N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0696-8 · Cited by 32
Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis
Avgerinos, I., Papanastasiou, G., Karagiannis, T., Michailidis, T., Liakos, A., Mainou, M., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14461 · Cited by 34
Lane, W. S., Favaro, E., Rathor, N., Jang, H. C., Kjaersgaard, M. I. S., Oviedo, A., Rose, L., Senior, P. A., Sesti, G., Gonzalez, A. S., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2232 · Cited by 26
“Moreover, fasteraspart improved 1-h PPG after a meal test, with no differences in overall hypoglycemia rates compared with IAsp (8).”
BackgroundTargeting One-Hour Postmeal Glucose: Is It Time for a Paradigm Switch in Diabetes Management?
Ceriello, A. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0135 · Cited by 28
“In the ONSET1 Trial, comparing fast acting aspart versus aspart in T1D, the overall rate of severe or blood glucoseconfirmed hypoglycemic episodes and safety profiles was similar between treatments, while in the ONSET2 Trial, comparing fast acting aspart versus aspart in T2D, the overall hypoglycemia rates were simila…”
Pharmacological Properties of Faster-Acting Insulin Aspart
Biester, T., Kordonouri, O., & Danne, T. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0931-y · Cited by 23
Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., et al. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-115964 · Cited by 24
Fast-acting insulin aspart: the rationale for a new mealtime insulin
Evans, M., Wilkinson, M., & Giannpolou, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00685-0 · Cited by 23
“The role of FAsp has been studied as part of a basal-bolus insulin regimen in people with type 2 diabetes [23, 24].”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 33
Nørgaard, S. K., Søholm, J. C., Mathiesen, E. R., Nørgaard, K., Clausen, T. D., Holmager, P., Do, N. C., Damm, P., & Ringholm, L. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00236-x · Cited by 24
Pal, R., Banerjee, M., & Bhadada, S. K. (2021) · Diabetic Medicine · doi:10.1111/dme.14515 · Cited by 21
Shiramoto, M., Nishida, T., Hansen, A. K., & Haahr, H. L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12697 · Cited by 19
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., & Owens, D. R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154935 · Cited by 22
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
Giorgino, F., Battelino, T., Bergenstal, R. M., Forst, T. M., Green, J. B., Mathieu, C., Rodbard, H. W., Schnell, O., & Wilmot, E. G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204584 · Cited by 20
“Several trials reported a statistically significant higher rate of hypoglycemia within the first two hours after a meal, 14,15,22,23,27 but a statistically significant lower rate of late postprandial hypoglycemic episodes.”
InfluentialPieber, T. R., Švehlíková, E., Brunner, M., Halberg, I. B., Thomsen, K. M. D., & Haahr, H. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13767 · Cited by 17
“It follows that the earlier suppression of FFA in the present study in T2D may contribute to the early improved postprandial glycaemic control seen with faster aspart versus IAsp.(17) For tmax, tGIRmax and offset of exposure and glucose-lowering effect, the present results indicate generally longer tails of the faster…”
MethodResultRole of ultrafast-acting insulin analogues in the management of diabetes
Kruger, D. F., & Novak, L. M. (2019) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000261 · Cited by 19
“Faster aspart, whose formulation has been optimized to achieve faster insulin absorption than RHI and conventional RAIAs, has shown promising results in clinical trials (Bowering et al., 2017; Buse et al., 2018; Mathieu et al., 2018; Rodbard et al., 2017; Russell-Jones et al., 2017; Zijlstra et al., 2018).”
ResultBally, L., Herzig, D., Ruan, Y., Wilinska, M. E., Semmo, M., Vogt, A. P., Wertli, M. M., Vogt, B., Stettler, C., & Hovorka, R. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13861 · Cited by 17
“Previous trials that evaluated the use of faster versus standard insulin aspart with injection and pump therapy reported no significant differences for overall glycaemic control between the two insulin formulations.(14-18) Several factors may explain the lack of improved glucose control during short-term application o…”
MethodLefever, E., Vliebergh, J., & Mathieu, C. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 17
RSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 16
Joshi, S., Jayanth, V., Loganathan, S., Sambandamurthy, V. K., & Athalye, S. N. (2023) · Drugs · doi:10.1007/s40265-023-01925-1 · Cited by 16
“There were much higher rates observed in other studies with rapid-acting insulins (event rate for IAsp was 1790 events PYE) [50].”
BackgroundResultInfluentialLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Navigating Insulin Options for Diabetes Management
Rafi, E., Tranchito, L. J., & Hatipoğlu, B. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae790 · Cited by 12
Corrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.06.015 · Cited by 18
Corrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.12.002 · Cited by 18
Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes
Block, C. E. M. D., Cauwenberghe, J. V., Bochanen, N., & Dirinck, E. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14713 · Cited by 13
Biosimilars and Novel Insulins
Ampudia‐Blasco, F. J. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001079 · Cited by 11
Advances in Care for Insulin-Requiring Patients Without Closed Loop
Lal, R., Buckingham, B. A., & Maahs, D. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0084 · Cited by 10
Glucose Targets and Insulin Choice in Pregnancy: What Has Changed in the Last Decade?
Bacon, S., & Feig, D. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1054-9 · Cited by 11
Bowering, K., Harvey, J., Kolaczynski, J. W., Snyder, J. W., & Bode, B. W. (2019) · Diabetic Medicine · doi:10.1111/dme.13866 · Cited by 8
Self-citationRecent and Upcoming Therapies for Management of Type 2 Diabetes: A Review
Gokalani, R. A., Saiyed, M., Dey, A. K., & Sheikh, F. (2024) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_12_24 · Cited by 8
Chawla, R., Mukherjee, J. J., Chawla, M. S., Kanungo, A. K., Shunmugavelu, M., & Das, A. K. (2021) · Medical Sciences · doi:10.3390/medsci9020038 · Cited by 10
“To target PPG, addition of a bolus insulin is one of he ptions [57].”
BackgroundInfluentialPietrzak, I., & Szadkowska, A. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.112621 · Cited by 8
Yacoub, T. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1389601 · Cited by 7
Baru, A., Amir, S., Ekelund, M., Montagnoli, R., & Fernandes, J. D. D. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1750181 · Cited by 7
“(T1D) [19,20] and type 2 diabetes (T2D) [21,22], where it”
BackgroundLeelarathna, L., Ashley, D., Fidler, C., & Parekh, W. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818766816 · Cited by 7
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2019)
Lechleitner, M., Kaser, S., Hofer, S., Hoppichler, F., Roden, M., Weitgasser, R., Fruehwald, L., Ludvik, B. H., Feder, A., Winhofer-Stöckl, Y., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1493-6 · Cited by 7
Type 1 Diabetes in Children and Adolescents
Sikes, K. A., Name, M. A. V., & Tamborlane, W. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_31 · Cited by 6
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“However, the relative risk of hypoglycaemia 0–2 h postprandially was significantly higher with fast insulin aspart (RR 1.60; 95 % CI 1.13–2.27) [228].”
InfluentialNew faster-acting insulin Fiasp® — do we need a new meal-time insulin?
Cypryk, K., & Wyrębska-Niewęgłowska, A. (2019) · Clinical Diabetology · doi:10.5603/dk.2018.0031 · Cited by 5
“019), no such difference was found within 2–4 hours after a meal [20].”
BackgroundLandgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0459-7 · Cited by 5
Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020
Chlup, R., Kaňa, R., Hanáčková, L., Zálešáková, H., & Doubravová, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96237 · Cited by 5
Bowering, K., Rodbard, H. W., Russell-Jones, D. L., Bode, B. W., Harris, S. B., Piletič, M., Heller, S. R., Woo, V. C., Babu, V., Dethlefsen, C., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0553-7 · Cited by 4
Self-citationPascual, E. L., Pérez, C. T., Muñoz‐Garach, A., & Ampudia‐Blasco, F. J. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.007 · Cited by 4
Biester, T., Berge, T. V. D., Bendtsen, L. Q., Bendtsen, M. D., Rathor, N., Danne, T., & Haahr, H. L. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13026 · Cited by 4
Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée
Monnier, L., Colette, C., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00178-4 · Cited by 5
Lane, W. S., Faurby, M. D., Husemoen, L. L. N., Markovich, D. L., Rathor, N., & Block, C. E. M. D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01165-0 · Cited by 5
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Ghosh, A. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666221222154443 · Cited by 4
Villar‐Taibo, R., Sanz-Pastor, A. G., Fernández-Rubio, E., Galindo, D. E. B., Simó-Servat, A., & Ampudia‐Blasco, F. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0524 · Cited by 4
“24, 32 In addition, five studies assessed URLi in comparison”
InfluentialLingvay, I., Catarig, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Evans, L. M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01344-7 · Cited by 3
Cutruzzolà, A., Parise, M., Fiorentino, R., Romano, A., Molinaro, V., Gnasso, A., Molfetta, S. D., & Irace, C. (2022) · Nutrients · doi:10.3390/nu14163316 · Cited by 4
“In some trials, Faster Aspart has been associated with a slightly increased risk of symptomatic hypoglycemia within the first two hours after a meal [25,27,29,32].”
BackgroundMizuno, S., Minatoya, M., Osaga, S., Chin, R., & Imori, M. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03050-1 · Cited by 3
“However, ultra-RAIAs such as URLi are more likely to cause severe hypoglycemia within 4 h of a meal [7, 9, 12, 24, 25].”
Zong, X., Xiao, S., Xia, H., Guo, D., Wu, J., Zhuang, M., & Rao, L. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s499641 · Cited by 4
Type 1 Diabetes in Children and Adolescents
Hu, P., Name, M. A. V., Stephenson, K., Sikes, K. A., & Tamborlane, W. V. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_30 · Cited by 3
Are newer insulins always the better option?
Malkani, S. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000469 · Cited by 2
Haahr, H. L., & Heise, T. (2020) · Diabetes Mellitus · doi:10.14341/dm12357 · Cited by 2
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2023)
Lechleitner, M., Kaser, S., Hoppichler, F., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Winhofer, Y., Kautzky‐Willer, A., Schernthaner, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02182-8 · Cited by 2
Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects
Суплотова, Л. А., & Tilkiyan, A. S. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-262 · Cited by 2
Fast-acting insulin aspart - from insulin portraits to patient portraits
Demidova, T. Y., & Izmaylova, M. Y. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-8-16 · Cited by 2
Insulines rapides et ultrarapides : quelles indications et utilités ?
Vuignier, Y., Wojtusciszyn, A., & Kosinski, C. (2022) · JMIG · doi:10.53738/revmed.2022.18.784.1110 · Cited by 2
Thomsen, C. H. N., Kronborg, T., Hangaard, S., Vestergaard, P., Hejlesen, O. K., & Jensen, M. H. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231201400 · Cited by 2
“18 Other antidiabetic treatment was disconnected.”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
Komatsu, M., Ekelund, M., Horio, H., & Kadowaki, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0606 · Cited by 2
“Mealtime faster aspart was effective in reducing PPG excursions in the Japanese participants, consistent with the results from the overall onset 8 trial population and the wider faster aspart clinical trial program [16, 18, 20-22].”
ResultGirsh, Y. V., Kiyaev, A. V., Slovak, M. A., Korneva, I. V., Промин, И. А., Yusupova, N. A., & Savelyev, L. I. (2022) · Diabetes Mellitus · doi:10.14341/dm12838 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Scherbaum, W. A., & Hamann, A. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0356-5 · Cited by 1
A prandialis glükózkontroll elérése gyors aszpart inzulinnal
Kis, J. T. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.8 · Cited by 1
Contrôle de la glycémie post-prandiale : apport des nouvelles formulations d’insuline ultra-rapides
Reznik, Y., & Jubin, L. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.09.004 · Cited by 1
Lane, W. S., Favaro, E., Jódar, E., Kelkar, P., Oviedo, A., Sivarathinasami, R., Senior, P. A., Sesti, G., & Franek, E. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01213-3 · Cited by 1
“Faster aspart has been shown to have an earlier onset and greater initial exposure and glucose-lowering effect [18], improved 1-h PPG control, with similar rates of hypoglycaemia compared with IAsp [19].”
ResultAu-delà des insulines actuelles : des réalisations prometteuses et quelques désillusions
Monnier, L., Colette, C., Azrak, A. E., Essekat, N., & Rochd, D. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.002 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
“Das relative Risiko von Hypoglykämien 0–2 Stunden postprandial war unter schnellem Insulin aspart jedoch signifikant höher (RR 1,60; 95%-KI 1,13–2,27) [145].”
Bode, B. W., Bowering, K., & Russell-Jones, D. L. (2018) · Diabetes Care · doi:10.2337/dci17-0051 · Cited by 1
Self-citationStoltenberg, C. W. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau766153770 · Cited by 1
Heise, T., & Biester, T. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-116018
“Sowohl bei Typ-1-Diabetes als auch bei Typ-2-Diabetes waren die Gesamt-Hypoglykämieraten sowie die Gewichtsentwicklung jeweils vergleichbar zwischen Faster-acting Insulin aspart und IAsp [30, 31].”
BackgroundInfluentialMöglichkeiten und Grenzen der aktuellen Insulintherapie
Forst, T. M. (2017) · Info Diabetologie · doi:10.1007/s15034-017-0976-7
Möglichkeiten und Grenzen der aktuellen Insulintherapie: Diabetes mellitus
Forst, T. M. (2018) · CME · doi:10.1007/s11298-018-6417-7
Wu, T., Marathe, C. S., Horowitz, M., Jones, K. L., & Rayner, C. K. (2018) · Diabetes Care · doi:10.2337/dc17-1916
“We read with interest the recent papers relating to the onset 1 and onset 2 trials (1,2), which compared the clinical efficacy and safety profiles of fast-acting insulin aspart (faster aspart) with insulin aspart (IAsp) in patients with type 1 and type 2 diabetes who concurrently received basal insulin.”
Background
Metadata
- Authors
- Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W.
- Affiliations
- University of Alberta (CA)
- Jefferson City Medical Group, Jefferson City, MO
- Bangor University (GB)
- Diabetes Clinical Trials, Chattanooga, TN
- Diabetes, Endocrinology and General Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, U.K.
- Protenium Clinical Research, Hurst, TX
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Bowering, Keith
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-05-08
- Volume
- 40
- Issue
- 7
- Pages
- 951-957
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2612230287
- Cited by
- 119
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 9 · 2023: 8 · 2022: 17 · 2021: 14 · 2020: 17 · 2019: 17 · 2018: 22 · 2017: 9
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin aspart, fast-acting insulin, multiple daily insulin injections, type 2 diabetes, inadequate glycemic control, HbA1c, postprandial blood glucose, hypoglycemia, insulin glargine, metformin, non-inferiority, insulin dose adjustment, oral antidiabetic drugs, body weight
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Postprandial Period, Endpoint Determination, Insulin Aspart, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.